[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
September 12, 2001

Treatment for Hepatitis C

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;286(10):1166. doi:10.1001/jama.286.10.1166-JFD10008-2-1

The FDA has issued two approvals involving the use of Rebetol capsules (ribavirin), Intron A injection (interferon alfa-2b) and PEG-Intron injection (peginterferon alfa-2b) (all Schering Corp, Kenilworth, NJ) to treat patients with chronic hepatitis C.

Rebetol capsules and Intron A had been approved as a single-package combination therapy for treatment of patients with chronic hepatitis C infection who have not had interferon therapy or who have relapsed following such therapy. The new approval provides for the distribution of Rebetol without Intron A, thereby giving prescribers flexibility in adopting individualized ribavirin- and interferon-based therapies.

First Page Preview View Large
First page PDF preview
First page PDF preview
×